» Santhera’s Positive Phase III Trial in Patients with DMD Published in The Lancet Action Duchenne

» Santhera’s Positive Phase III Trial in Patients with DMD Published in The Lancet Action Duchenne: "The results of the DELOS trial demonstrated that Raxone/Catena significantly reduced the annual decline in Peak Expiratory Flow (PEF as percent predicted, PEF%p) by 66% compared to patients taking placebo. Other respiratory function endpoints such as Forced Vital Capacity (FVC) and Forced Expiratory Volume (FEV1) corroborated these results and showed a consistent pattern with treatment differences supporting efficacy of Raxone/Catena over placebo in the preservation of respiratory function. Researchers concluded that Raxone/Catena represents a new treatment option for DMD patients."



'via Blog this'